Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations
D Focosi, M Franchini - Expert review of vaccines, 2022 - Taylor & Francis
Expert review of vaccines, 2022•Taylor & Francis
ABSTRACT Introduction: The ongoing SARS-CoV-2 pandemic is a serious threat for the
health of immunocompromised patients. Among neutralizing antibody-based therapeutics,
convalescent plasma containing polyclonal anti-SARS-CoV-2 immunoglobulins has
promising results in both congenital and iatrogenic immunodeficiencies in
oncohematological and transplant patients. Areas covered: This article discusses case
reports, case series and controlled studies detailing the efficacy of convalescent plasma in …
health of immunocompromised patients. Among neutralizing antibody-based therapeutics,
convalescent plasma containing polyclonal anti-SARS-CoV-2 immunoglobulins has
promising results in both congenital and iatrogenic immunodeficiencies in
oncohematological and transplant patients. Areas covered: This article discusses case
reports, case series and controlled studies detailing the efficacy of convalescent plasma in …
Introduction
: The ongoing SARS-CoV-2 pandemic is a serious threat for the health of immunocompromised patients. Among neutralizing antibody-based therapeutics, convalescent plasma containing polyclonal anti-SARS-CoV-2 immunoglobulins has promising results in both congenital and iatrogenic immunodeficiencies in oncohematological and transplant patients.
Areas covered
: This article discusses case reports, case series and controlled studies detailing the efficacy of convalescent plasma in immunocompromised patients.
Expert opinion
: Convalescent plasma, when administered at high neutralizing antibody titers, is a safe and effective treatment for frail immunocompromised patients. Genetic monitoring of refractory patients is recommended to intercept intra-host emergence of SARS-CoV-2 variants.
Taylor & Francis Online以上显示的是最相近的搜索结果。 查看全部搜索结果